Fenwick Represents Impel NeuroPharma in $36 Million Series C Financing

Fenwick & West represented Impel NeuroPharma, Inc., a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders, in its $35 million Series C financing. The round was led equally by venBio, 5AM Ventures and Vivo Capital.

More information about Impel NeuroPharma’s $36 million Series C financing can be obtained from the company press release.

The Fenwick transaction team was led by corporate lawyers Alan Smith, Matthew Karwoski and Hans Andersson; intellectual property lawyer Dan Becker; and technology transactions attorney Stefano Quintini.